198 related articles for article (PubMed ID: 36468020)
1. Clinical value of M1 macrophage-related genes identification in bladder urothelial carcinoma and
Yu Y; Huang Y; Li C; Ou S; Xu C; Kang Z
Front Genet; 2022; 13():1047004. PubMed ID: 36468020
[No Abstract] [Full Text] [Related]
2. Clinical Eosinophil-Associated Genes can Serve as a Reliable Predictor of Bladder Urothelial Cancer.
Xu C; Song L; Peng H; Yang Y; Liu Y; Pei D; Guo J; Liu N; Liu J; Li X; Li C; Kang Z
Front Mol Biosci; 2022; 9():963455. PubMed ID: 35936781
[No Abstract] [Full Text] [Related]
3. Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and
Dong Y; Xu C; Su G; Li Y; Yan B; Liu Y; Yin T; Mou S; Mei H
Front Immunol; 2023; 14():1122570. PubMed ID: 37275895
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma.
Chen L; Lin J; Wen Y; Chen Y; Chen CB
Front Oncol; 2023; 13():1291720. PubMed ID: 38023241
[TBL] [Abstract][Full Text] [Related]
5. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Novel Tumor Microenvironment Prognostic Signature for Bladder Urothelial Carcinoma.
Xu C; Pei D; Liu Y; Yu Y; Guo J; Liu N; Kang Z
Front Oncol; 2022; 12():818860. PubMed ID: 35299749
[TBL] [Abstract][Full Text] [Related]
7. Clinical M2 Macrophage-Related Genes Can Serve as a Reliable Predictor of Lung Adenocarcinoma.
Xu C; Song L; Yang Y; Liu Y; Pei D; Liu J; Guo J; Liu N; Li X; Liu Y; Li X; Yao L; Kang Z
Front Oncol; 2022; 12():919899. PubMed ID: 35936688
[TBL] [Abstract][Full Text] [Related]
8. Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures.
Dong Y; Wu X; Xu C; Hameed Y; Abdel-Maksoud MA; Almanaa TN; Kotob MH; Al-Qahtani WH; Mahmoud AM; Cho WC; Li C
Aging (Albany NY); 2024 Feb; 16(3):2591-2616. PubMed ID: 38305808
[TBL] [Abstract][Full Text] [Related]
9. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
Pan G; Xie H; Xia Y
Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551
[TBL] [Abstract][Full Text] [Related]
10. Exploring the Shared Gene Signatures and Molecular Mechanisms between Bladder Urothelial Carcinoma and Metabolic Syndrome.
Li C; Wan Z; Deng Q; Li Z; Wang Y
Arch Esp Urol; 2023 Oct; 76(8):605-621. PubMed ID: 37960960
[TBL] [Abstract][Full Text] [Related]
11. Construction of cancer- associated fibroblasts related risk signature based on single-cell RNA-seq and bulk RNA-seq data in bladder urothelial carcinoma.
Liu Y; Jian J; Zhang Y; Wang L; Liu X; Chen Z
Front Oncol; 2023; 13():1170893. PubMed ID: 37124542
[TBL] [Abstract][Full Text] [Related]
12. Construction and verification of a novel hypoxia-related lncRNA signature related with survival outcomes and immune microenvironment of bladder urothelial carcinoma by weighted gene co-expression network analysis.
Cai D; Zhou Z; Wei G; Wu P; Kong G
Front Genet; 2022; 13():952369. PubMed ID: 36118856
[No Abstract] [Full Text] [Related]
13. Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
Cao M; Cao Y; Xue S; Zhang Q; Zhang H; Xue W
Altern Ther Health Med; 2024 Apr; 30(4):130-138. PubMed ID: 38518167
[TBL] [Abstract][Full Text] [Related]
14. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
15. Development and Validation of a Prognostic Gene Signature Correlated With M2 Macrophage Infiltration in Esophageal Squamous Cell Carcinoma.
Yao J; Duan L; Huang X; Liu J; Fan X; Xiao Z; Yan R; Liu H; An G; Hu B; Ge Y
Front Oncol; 2021; 11():769727. PubMed ID: 34926275
[TBL] [Abstract][Full Text] [Related]
16. Generalized machine learning based on multi-omics data to profile the effect of ferroptosis pathway on prognosis and immunotherapy response in patients with bladder cancer.
Liu X; Qiu Z; Zhang X; Su Z; Yi R; Zou D; Xie C; Jin N; Long W; Liu X
Environ Toxicol; 2024 Feb; 39(2):680-694. PubMed ID: 37647346
[TBL] [Abstract][Full Text] [Related]
17. In silico development and experimental validation of a novel 7-gene signature based on PI3K pathway-related genes in bladder cancer.
Wang L; Wang Y; Bi J
Funct Integr Genomics; 2022 Oct; 22(5):797-811. PubMed ID: 35896848
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
[TBL] [Abstract][Full Text] [Related]
19. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
Front Immunol; 2022; 13():965469. PubMed ID: 36090967
[TBL] [Abstract][Full Text] [Related]
20. Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.
Dong B; Liang J; Li D; Song W; Zhao S; Ma Y; Song J; Zhu M; Yang T
Front Genet; 2021; 12():696912. PubMed ID: 34512722
[No Abstract] [Full Text] [Related]
[Next] [New Search]
